Hangzhou Jiuyuan

Hangzhou Jiuyuan Genetic Biopharmaceutical is a leading Chinese biopharmaceutical company specializing in the development, manufacturing, and commercialization of biologics and medical devices. Founded in 1993 and headquartered in Hangzhou, the company focuses on four core therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Its commercial portfolio includes prominent products such as JILIFEN (filgrastim), GUYOUDAO (rhBMP-2), and YINUOJIA (enoxaparin). Jiuyuan Gene is notably the first company in China to submit a Biologics License Application for a semaglutide biosimilar (JY09). The company was listed on the Hong Kong Stock Exchange in November 2024 (HKEX: 2566) and maintains a strategic relationship with Huadong Medicine.